RBC Capital Sticks to Their Hold Rating for Inovio Pharmaceuticals (INO)
In a report released yesterday, Gregory Renza from RBC Capital maintained a Hold rating on Inovio Pharmaceuticals (INO – Research Report), with a price target of $5.00. The company’s shares closed yesterday at $2.10.
Light Up your Portfolio with Spark:
- Easily identify stocks' risks and opportunities.
- Discover stocks' market position with detailed competitor analyses.
Renza covers the Healthcare sector, focusing on stocks such as Exelixis, Nuvation Bio, and Amgen. According to TipRanks, Renza has an average return of 7.7% and a 42.28% success rate on recommended stocks.
In addition to RBC Capital, Inovio Pharmaceuticals also received a Hold from H.C. Wainwright’s Yi Chen in a report issued yesterday. However, today, JMP Securities reiterated a Buy rating on Inovio Pharmaceuticals (NASDAQ: INO).
Based on Inovio Pharmaceuticals’ latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $25.17 billion. In comparison, last year the company earned a revenue of $388.45 thousand and had a GAAP net loss of $33.93 million
Read More on INO:
Questions or Comments about the article? Write to editor@tipranks.com- Inovio Pharmaceuticals: Hold Rating Amid Promising Developments and Financial Challenges
- Inovio price target lowered to $12 from $18 at Citizens JMP
- Inovio Pharmaceuticals Reports 2024 Financial Results
- Inovio reports Q4 EPS (65c), consensus (83c)
- Inovio options imply 8.1% move in share price post-earnings
